Table 1.
Patient, disease, and treatment characteristics
| Characteristics | N (%) or median (range) |
|---|---|
| No. of patients | 18 |
| Age, y | 30.5 (range 23-55) |
| No. of prior regimens | 4.5 (range 3-8) |
| Prior auto-HCT | 17 (94.4) |
| Previous XRT | 10 (55.6) |
| Best response to brentuximab vedotin | |
| CR | 7 (39) |
| PR | 8 (44) |
| SD | 2 (11) |
| PD | 1 (6) |
| No. of cycles of brentuximab vedotin | 7 (range 2-16) |
| Baseline neuropathy before allo-HCT | 68 (44) |
| Grade 1 | 6 (33) |
| Grade 2 | 2 (11) |
| Disease status after brentuximab vedotin | |
| CR | 6 (33) |
| PR | 6 (33) |
| SD | 1 (6) |
| PD | 5 (28) |
| Disease status at allo-HCT | |
| CR | 6 (33) |
| PR | 8 (44) |
| SD | 1 (6) |
| PD | 3 (17) |
| Time from brentuximab vedotin to allo-HCT | 62 d (range 24-276) |
| Type of transplantation | |
| MRD | 7 (39) |
| MUD | 8 (44) |
| Haplo | 3 (17) |
| Conditioning regimen | |
| Flu/Mel | 14 (77) |
| Flu/Cy/TBI | 3 (17) |
| 2 Gy TBI | 1 (6) |
| GVHD prophylaxis | |
| Tacro/Siro | 10 (55) |
| Tacro/Siro/MTX | 2 (11) |
| Cy/Tac/MMF | 3 (17) |
| CSA/MMF | 1 (6) |
| CSA/MTX | 2 (11) |
XRT indicates irradiation; SD, stable disease; PD, progressive disease; MRD, matched related donor; MUD, matched unrelated donor; Haplo, haploidentical; Flu, fludarabine; Mel, melphalan; TBI, total body irradiation; Tacro, tacrolimus; Siro, sirolimus; Cy, cyclophosphamide; Tac, tacrolimus; MMF, mycophenolate mofetil; CSA, cyclosporine A; ATG, antithymocyte globulin; and MTX, methotrexate.